Rong Huang1, Jing Zhu2, Lin Zhang3, Xiaolin Hua3, Weiping Ye3, Chang Chen4, Kun Sun5, Weiye Wang1, Liping Feng6, Jun Zhang7. 1. Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China. 2. Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China; Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4. Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 5. Department of Pediatric Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, China. 6. Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China; Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: liping.feng@duke.edu. 7. Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: junjimzhang@sina.com.
Abstract
OBJECTIVE: We aimed to examine the ELABELA levels at different stages of pregnancy among normotensive controls and women with hypertensive disorders of pregnancy (HDP). STUDY DESIGN: A total of 336 blood samples of 169 women were collected from pre-pregnancy, the first, second, and third trimesters. Women were divided into the following six groups: 1) non-pregnant healthy women; 2) healthy pregnant controls; 3) chronic hypertension; 4) gestational hypertension; 5) preeclampsia; and 6) preeclampsia superimposed on chronic hypertension. ELABELA plasma concentrations were measured by human ELA Elisa Kit (Peninsula Laboratories International, Inc. USA). Kruskal-Wallis test was used to test whether ELABELA level in each type of HDP differed from that in gestational week-matched normotensive controls. MAIN OUTCOME MEASURES: Hypertensive disorders of pregnancy. RESULTS: In the first trimester, patients with gestational hypertension had higher ELABELA level than gestational week-matched normotensive controls [median (ng/ml): 31.9, (IQR (ng/ml): 16.3, 47.6) vs. 19.7 (13.7, 23.2), p = 0.03]. In the second trimester, the levels were 49.2 (32.2, 69.1) vs 24.0 (13.0, 32.6) (p = 0.002), respectively. The level for gestational hypertensive women in the third trimester did not differ significantly from that of normotensive women [43.8 (30.8, 62.7) vs 25.0 (12.3, 74.0), p = 0.82]. The ELABELA levels were similar between preeclamptic women and normotensive controls throughout pregnancy. CONCLUSIONS: Maternal blood ELABELA levels in the first and second trimesters were elevated in women who developed gestational hypertension late in pregnancy, but the ELABELA level bears no significant relationship with preeclampsia during any stage of pregnancy.
OBJECTIVE: We aimed to examine the ELABELA levels at different stages of pregnancy among normotensive controls and women with hypertensive disorders of pregnancy (HDP). STUDY DESIGN: A total of 336 blood samples of 169 women were collected from pre-pregnancy, the first, second, and third trimesters. Women were divided into the following six groups: 1) non-pregnant healthy women; 2) healthy pregnant controls; 3) chronic hypertension; 4) gestational hypertension; 5) preeclampsia; and 6) preeclampsia superimposed on chronic hypertension. ELABELA plasma concentrations were measured by human ELA Elisa Kit (Peninsula Laboratories International, Inc. USA). Kruskal-Wallis test was used to test whether ELABELA level in each type of HDP differed from that in gestational week-matched normotensive controls. MAIN OUTCOME MEASURES: Hypertensive disorders of pregnancy. RESULTS: In the first trimester, patients with gestational hypertension had higher ELABELA level than gestational week-matched normotensive controls [median (ng/ml): 31.9, (IQR (ng/ml): 16.3, 47.6) vs. 19.7 (13.7, 23.2), p = 0.03]. In the second trimester, the levels were 49.2 (32.2, 69.1) vs 24.0 (13.0, 32.6) (p = 0.002), respectively. The level for gestational hypertensivewomen in the third trimester did not differ significantly from that of normotensive women [43.8 (30.8, 62.7) vs 25.0 (12.3, 74.0), p = 0.82]. The ELABELA levels were similar between preeclamptic women and normotensive controls throughout pregnancy. CONCLUSIONS: Maternal blood ELABELA levels in the first and second trimesters were elevated in women who developed gestational hypertension late in pregnancy, but the ELABELA level bears no significant relationship with preeclampsia during any stage of pregnancy.
Authors: Lena Ho; Marie van Dijk; Sam Tan Jian Chye; Daniel M Messerschmidt; Serene C Chng; Sheena Ong; Ling Ka Yi; Souad Boussata; Grace Hui-Yi Goh; Gijs B Afink; Chin Yan Lim; N Ray Dunn; Davor Solter; Barbara B Knowles; Bruno Reversade Journal: Science Date: 2017-06-29 Impact factor: 47.728
Authors: Lena Ho; Shawn Y X Tan; Sheena Wee; Yixuan Wu; Sam J C Tan; Navin B Ramakrishna; Serene C Chng; Srikanth Nama; Iwona Szczerbinska; Iwona Sczerbinska; Yun-Shen Chan; Stuart Avery; Norihiro Tsuneyoshi; Huck Hui Ng; Jayantha Gunaratne; N Ray Dunn; Bruno Reversade Journal: Cell Stem Cell Date: 2015-09-17 Impact factor: 24.633
Authors: Kathleen A Pennington; Jessica M Schlitt; Daniel L Jackson; Laura C Schulz; Danny J Schust Journal: Dis Model Mech Date: 2012-01 Impact factor: 5.758
Authors: Natasha Pritchard; Tu'uhevaha J Kaitu'u-Lino; Sungsam Gong; Justyna Dopierala; Gordon C S Smith; D Stephen Charnock-Jones; Stephen Tong Journal: Am J Pathol Date: 2018-05-24 Impact factor: 4.307